Genotype-based risk and pharmacogenetic sampling in clinical trials

Journal of Biopharmaceutical Statistics

Volumn 20, Issue 2, 2010, Pages 315-333

  Schork, Nicholas J ^a   Topol, Eric J ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

DNA sequencing; Drug validation; Polymorphism; Study design; Translational medicine

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ANTIOXIDANT; ATORVASTATIN; CLOPIDOGREL; FIBRINOLYTIC AGENT; FINASTERIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; METFORMIN; RAMIPRIL; SIMVASTATIN;

ALZHEIMER DISEASE; ARTICLE; BEHAVIOR THERAPY; CLINICAL STUDY; CLINICAL TRIAL; DISEASE ASSOCIATION; DRUG EFFICACY; GENETIC ASSOCIATION; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTYPE; HEART DISEASE; HEART INFARCTION; HUMAN; MULTILOCUS SEQUENCE TYPING; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PATIENT SELECTION; PHARMACOGENETICS; PRIORITY JOURNAL; PROPHYLAXIS; PROSTATE CANCER; RETINA MACULA DEGENERATION; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE;

ALZHEIMER DISEASE; CLINICAL TRIALS AS TOPIC; DATA INTERPRETATION, STATISTICAL; DIABETES MELLITUS, TYPE 2; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOME-WIDE ASSOCIATION STUDY; HEART DISEASES; HUMANS; MACULAR DEGENERATION; MALE; MODELS, STATISTICAL; OBESITY; PHARMACOGENETICS; PHENOTYPE; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSTATIC NEOPLASMS; RISK ASSESSMENT; RISK FACTORS; SAMPLE SIZE; TREATMENT OUTCOME;

EID: 77951286625     PISSN: 10543406     EISSN: 15205711     Source Type: Journal    
DOI: 10.1080/10543400903572779     Document Type: Article

References (41)

1. Aulchenko, Y. S., Ripatti, S., Lindqvist, I., Boomsma, D., Heid, I. M., Pramstaller, P. P., Penninx, B. W., Janssens, A. C., Wilson, J. F., Spector, T., Martin, N. G., Pedersen, N. L., Kyvik, K. O., Kaprio, J., Hofman, A., Freimer, N. B., Jarvelin, M. R., Gyllensten, U., Campbell, H., Rudan, I., Johansson, A., Marroni, F., Hayward, C., Vitart, V., Jonasson, I., Pattaro, C., Wright, A., Hastie, N., Pichler, I., Hicks, A. A., Falchi, M., Willemsen, G., Hottenga, J. J., de Geus, E. J., Montgomery, G. W., Whitfield, J., Magnusson, P., Saharinen, J., Perola, M., Silander, K., Isaacs, A., Sijbrands, E. J., Uitterlinden, A. G., Witteman, J. C., Oostra, B. A., Elliott, P., Ruokonen, A., Sabatti, C., Gieger, C., Meitinger, T., Kronenberg, F., Döring, A., Wichmann, H. E., Smit, J. H., McCarthy, M. I., van Duijn, C. M., Peltonen, L., ENGAGE Consortium. (2009). Loci influencing lipid levels and coronary heart disease risk in 16 European population cohorts. Nat. Genet. 41(1):47-55. Epub 2008 Dec 7. PMID: 19060911.
2. Antiplatelet Trialists' Collaboration. (1994). Collaborative overview of randomised trials of antiplatelet therapy-I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration. Br. Med. J. 308(6921):81-106. Erratum in: Br. Med. J. (1994). 308(6943):1540
3. Baigent, C., Keech, A., Kearney, P. M., Blackwell, L., Buck, G., Pollicino, C., Kirby, A., Sourjina, T., Peto, R., Collins, R., Simes, R., Cholesterol Treatment Trialists' (CTT) Collaborators. (2005). Efficacy and safety of cholesterol-lowering treatment: Prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 366(9493):1267-1278. Epub 2005 Sep 27. Erratum in: Lancet (2005). 366(9494):1358.
4. Bouatia-Naji, N., Bonnefond, A., Cavalcanti-Proença, C., Sparsø, T., Holmkvist, J., Marchand, M., Delplanque, J., Lobbens, S., Rocheleau, G., Durand, E., De Graeve, F., Chèvre, J. C., Borch-Johnsen, K., Hartikainen, A. L., Ruokonen, A., Tichet, J., Marre, M., Weill, J., Heude, B., Tauber, M., Lemaire, K., Schuit, F., Elliott, P., Jørgensen, T., Charpentier, G., Hadjadj, S., Cauchi, S., Vaxillaire, M., Sladek, R., Visvikis-Siest, S., Balkau, B., Lévy-Marchal, C., Pattou, F., Meyre, D., Blakemore, A. I., Jarvelin, M. R., Walley, A. J., Hansen, T., Dina, C., Pedersen, O., Froguel, P. (2009). A variant near MTNR1B is associated with increased fasting plasma glucose levels and type 2 diabetes risk. Nat. Genet. 41(1):89-94. Epub 2008 Dec 7. :19060909.
5. Brandt, J. T., Close, S. L., Iturria, S. J., Payne, C. D., Farid, N. A., Ernest, C. S. 2nd, Lachno, D. R., Salazar, D., Winters, K. J. (2007). Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel. J. Thromb. Haemost. 5(12): 2429-2436. Epub 2007 Sep 26. PMID: 17900275
6. Butler, D. (2008). Translational research: crossing the valley of death. Nature 453(7197):840-842. No abstract available. PMID: 18548043.
7. Cardon, L. R., Idury, R. M., Harris, T. J., Witte, J. S., Elston, R. C. (2000). Testing drug response in the presence of genetic information: sampling issues for clinical trials. Pharmacogenetics 10(6):503-510.
8. Coon, K. D., Myers, A. J., Craig, D. W., Webster, J. A., Pearson, J. V., Lince, D. H., Zismann, V. L., Beach, T. G., Leung, D., Bryden, L., Halperin, R. F., Marlowe, L., Kaleem, M., Walker, D. G., Ravid, R., Heward, C. B., Rogers, J., Papassotiropoulos, A., Reiman, E. M., Hardy, J., Stephan, D. A. (2007). A highdensity whole-genome association study reveals that APOE is the major susceptibility gene for sporadic late-onset Alzheimer's disease. J. Clin. Psychiatry 68(4):613-618.
9. Diabetes Genetics Initiative of Broad Institute of Harvard and MIT, Lund University, and Novartis Institutes of BioMedical Research, Saxena, R., Voight, B. F., Lyssenko, V., Burtt, N P., de Bakker, P. I., Chen, H., Roix, J. J., Kathiresan, S., Hirschhorn, J. N., Daly, M. J., Hughes, T. E., Groop, L., Altshuler, D., Almgren, P., Florez, J. C., Meyer, J., Ardlie, K., Bengtsson Boström, K., Isomaa, B., Lettre, G., Lindblad, U., Lyon, H. N., Melander, O., Newton-Cheh, C., Nilsson, P., Orho-Melander, M., Råstam, L., Speliotes, E. K., Taskinen, M. R., Tuomi, T., Guiducci, C., Berglund, A., Carlson, J., Gianniny, L., Hackett, R., Hall, L., Holmkvist, J., Laurila, E., Sjögren, M., Sterner, M., Surti, A., Svensson, M., Svensson, M., Tewhey, R., Blumenstiel, B., Parkin, M., Defelice, M., Barry, R., Brodeur, W., Camarata, J., Chia, N., Fava, M., Gibbons, J., Handsaker, B., Healy, C., Nguyen, K., Gates, C., Sougnez, C., Gage, D., Nizzari, M., Gabriel, S. B., Chirn, G. W., Ma, Q., Parikh, H., Richardson, D., Ricke, D., Purcell, S. (2007). Genome-wide association analysis identifies loci for type 2 diabetes and triglyceride levels. Science 316(5829):1331-1336. Epub 2007 Apr 26.
10. Dina, C., Meyre, D., Gallina, S., Durand, E., Körner, A., Jacobson, P., Carlsson, L. M., Kiess, W., Vatin, V., Lecoeur, C., Delplanque, J., Vaillant, E., Pattou, F., Ruiz, J., Weill, J., Levy-Marchal, C., Horber, F., Potoczna, N., Hercberg, S., Le Stunff, C., Bougnères, P., Kovacs, P., Marre, M., Balkau, B., Cauchi, S., Chèvre, J. C., Froguel, P. (2007). Variation in FTO contributes to childhood obesity and severe adult obesity. Nat. Genet. 39(6):724-726. Epub 2007 May 13.
11. Elston, R. C., Idury, R. M., Cardon, L. R., Lichter, J. B. (1999). The study of candidate genes in drug trials: sample size considerations. Stat. Med. 18(6):741-751.
12. EPIC Investigation. (1994). Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. The EPIC Investigation. N. Engl. J. Med. 330(14):956-961.
13. Fibrinolytic Therapy Trialists' (FTT) Collaborative Group. (1994). Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Fibrinolytic Therapy Trialists' (FTT) Collaborative Group. Lancet 343(8893):311-322. Review. Erratum in: Lancet (1994). 343(8899):742.
14. Fijal, B. A., Hall, J. M., Witte, J. S. (2000). Clinical trials in the genomic era: Effects of protective genotypes on sample size and duration of trial. Control. Clin. Trials 21(1):7-20.
15. Fleiss, J. L., Levin, B., Paik, M. C. (2003). Statistical Methods for Rates and Proportions. Hoboken, NJ: John Wiley & Sons.
16. Gortmaker, S. L., Peterson, K., Wiecha, J., Sobol, A. M., Dixit, S., Fox, M. K., Laird, N. (1999). Reducing obesity via a school-based interdisciplinary intervention among youth: Planet Health. Arch. Pediatr. Adolesc. Med. 153(4):409-418.
17. Heart Protection Study Collaborative Group. (2002). MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20,536 high-risk individuals: A randomised placebo-controlled trial. Lancet 360(9326):23-33. Summary for patients in: J. Fam. Pract. (2002). 51(10):810.
18. Helgadottir, A., Thorleifsson, G., Manolescu, A., Gretarsdottir, S., Blondal, T., Jonasdottir, A., Jonasdottir, A., Sigurdsson, A., Baker, A., Palsson, A., Masson, G., Gudbjartsson, D. F., Magnusson, K. P., Andersen, K., Levey, A. I., Backman, V. M., Matthiasdottir, S., Jonsdottir, T., Palsson, S., Einarsdottir, H., Gunnarsdottir, S., Gylfason, A., Vaccarino, V., Hooper, W. C., Reilly, M. P., Granger, C. B., Austin, H., Rader, D. J., Shah, S. H., Quyyumi, A. A., Gulcher, J. R., Thorgeirsson, G., Thorsteinsdottir, U., Kong, A., Stefansson, K. (2007). A common variant on chromosome 9p21 affects the risk of myocardial infarction. Science 316(5830):1491-1493. Epub 2007 May 3. PMID: 17478679. (Pubitemid 46906618)
19. Karapetis, C. S., Khambata-Ford, S., Jonker, D. J., O'Callaghan, C. J., Tu, D., Tebbutt, N. C., Simes, R. J., Chalchal, H., Shapiro, J. D., Robitaille, S., Price, T. J., Shepherd, L., Au, H. J., Langer, C., Moore, M. J., Zalcberg, J. R. (2008). K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N. Engl. J. Med. 359(17):1757-1765. PMID: 18946061.
20. Kjekshus, J., Pedersen, T. R. (1995). Reducing the risk of coronary events: Evidence from the Scandinavian simvastatin survival study (45). American Journal of Cardiology 76(9):64c-68c.
21. LaRosa, J. C., Grundy, S. M., Waters, D. D., Shear, C., Barter, P., Fruchart, J. C., Gotto, A. M., Greten, H., Kastelein, J. J., Shepherd, J., Wenger, N. K. (2005). Treating to New Targets (TNT) Investigators. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N. Engl. J. Med. 352(14):1425-1435. Epub 2005 Mar 8.
22. Liao, G., Zhang, X., Clark, D. J., Peltz. (2008). A genomic "roadmap" to "better" drugs. Drug Metab. Rev. 40(2):225-239. Review. PMID: 18464044.
23. Liggett, S. B., Cresci, S., Kelly, R. J., Syed, F. M., Matkovich, S. J., Hahn, H. S., Diwan, A., Martini, J. S., Sparks, L., Parekh, R. R., Spertus, J. A., Koch, W. J., Kardia, S.L., Dorn, G. W. 2nd. (2008). A GRK5 polymorphism that inhibits beta-adrenergic receptor signaling is protective in heart failure. Nat. Med. 14(5):510-517. Epub 2008 Apr 20. PMID: 18425130.
24. Lu, Q., Obuchowski, N., Won, S., Zhu, X., Elston, R. C. (2009). Using the optimal robust receiver operating characteristic (ROC) curve for predictive genetic tests. Biometrics June 8. [Epub ahead of print] PMID: 19508241.
25. Lyssenko, V., Jonsson, A., Almgren, P., Pulizzi, N., Isomaa, B., Tuomi, T., Berglund, G., Altshuler, D., Nilsson, P., Groop, L. (2008). Clinical risk factors, DNA variants, and the development of type 2 diabetes. N. Engl. J. Med. 359(21):2220-2232. PMID: 19020324.
26. Maitournam, A., Simon, R. (2005). On the efficiency of targeted clinical trials. Stat. Med. 24(3):329-339.
27. Manolio, T. A., Brooks, L. D., Collins, F. S. (2008). A HapMap harvest of insights into the genetics of common disease. J. Clin. Invest. 118(5):1590-1605. Review. PMID: 18451988.
28. Mukherjee, D., Topol, E. J. (2002). Pharmacogenomics in cardiovascular diseases. Prog. Cardiovasc. Dis. 44(6):479-498. Review.
29. Salpeter, S. R., Buckley, N. S., Kahn, J. A., Salpeter, E. E. (2008). Meta-analysis: Metformin treatment in persons at risk for diabetes mellitus. Am. J. Med. 121(2):149-157.e2. Review.
30. Schlesselman, J. J. (1982). Case-Control Studies: Design, Conduct, Analysis. New York: Oxford University Press.
31. Schork, N. J., Weder, A. B. (1996). The use of genetic information in large-scale clinical trials: Applications to Alzheimer research. Alzheimer Dis. Assoc. Disorders 10 (suppl. 1):22-26.
32. SEARCH Collaborative Group, Link, E., Parish, S., Armitage, J., Bowman, L., Heath, S., Matsuda, F., Gut, I., Lathrop, M., Collins, R. (2008). SLCO1B1 variants and statininduced myopathy-A genomewide study. N. Engl. J. Med. 359(8):789-799. Epub 2008 Jul 23. PMID: 18650507.
33. Simon, R. (2006). Validation of pharmacogenomic biomarker classifiers for treatment selection. Cancer Biomarkers 2(3-4):89-96. Review.
34. Simon, R. (2007). New challenges for 21st century clinical trials. Clin. Trials 4(2):167-169. No abstract available.
35. Simon, R., Maitournam, A. (2004). Evaluating the efficiency of targeted designs for randomized clinical trials. Clin. Cancer Res. 10(20):6759-6763. Erratum in: Clin. Cancer Res. (2006). 12(10):3229
36. Talmud, P. J., Cooper, J. A., Palmen, J., Lovering, R., Drenos, F., Hingorani, A. D., Humphries, S. E. (2008). Chromosome 9p21.3 coronary heart disease locus genotype and prospective risk of CHD in healthy middle-aged men. Clin. Chem. 54(3):467-474. Epub 2008 Feb 4. PMID: 18250146.
37. Thompson, I. M., Goodman, P. J., Tangen, C. M., Lucia, M. S., Miller, G. J., Ford, L. G., Lieber, M. M., Cespedes, R. D., Atkins, J. N., Lippman, S. M., Carlin, S. M., Ryan, A., Szczepanek, C. M., Crowley, J. J., Coltman, C. A., Jr. (2003). The influence of finasteride on the development of prostate cancer. N. Engl. J. Med. 349(3):215-224. Epub 2003 Jun 24.
38. Trepicchio, W. L., Essayan, D., Hall, S. T., Schechter, G., Tezak, Z., Wang, S. J., Weinreich, D., Simon, R. (2006). Designing prospective clinical pharmacogenomic (PG) trials: Meeting report on drug development strategies to enhance therapeutic decision making. Pharmacogenomics J. 6(2):89-94. No abstract available.
39. Yusuf, S., Sleight, P., Pogue, J., Bosch, J., Davies, R., Dagenais, G. (2000). Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in highrisk patients: The Heart Outcomes Prevention Evaluation Study Investigators. N. Engl. J. Med. 342(3):145-153. (Pubitemid 30051645)
40. Yusuf, S., Zhao, F., Mehta, S. R., Chrolavicius, S., Tognoni, G., Fox, K. K. (2001). Clopidogrel in unstable angina to prevent recurrent events trial investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N. Eng.l J. Med. 345(7):494-502. Erratum in: N. Engl. J. Med.(2001). 345(23):1716. N. Engl. J. Med. (2001). 345(20):1506.
41. Zheng, S. L., Sun, J., Wiklund, F., Smith, S., Stattin, P., Li, G., Adami, H. O., Hsu, F. C., Zhu, Y., Bälter, K., Kader, A. K., Turner, A. R., Liu, W., Bleecker, E. R., Meyers, D. A., Duggan, D., Carpten, J. D., Chang, B. L., Isaacs, W. B., Xu, J., Grönberg, H. (2008). Cumulative association of five genetic variants with prostate cancer. N. Engl. J. Med. Jan 16 [Epub ahead of print].